The nonsteroidal antiinflammatory drug piroxicam reverses the onset of depressive-like behavior in 6-OHDA animal model of Parkinson's disease

Neuroscience

Volumn 300, Issue , 2015, Pages 246-253

  Santiago, R M ^a   Tonin, F S ^a   Barbiero, J ^a   Zaminelli, T ^a   Boschen, S L ^a   Andreatini, R ^a   Da Cunha, C ^a   Lima, M M S ^a   Vital, M A B F ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

6 OHDA; Depression; Parkinson's disease; Piroxicam

Indexed keywords

BRAIN MONOAMINE; OXIDOPAMINE; PIROXICAM; SEROTONIN; 5 HYDROXYINDOLEACETIC ACID; ANTIDEPRESSANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SUGAR INTAKE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DEPRESSION; FORCED SWIM TEST; HIPPOCAMPUS; LONG TERM CARE; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SUBSTANTIA NIGRA; SUCROSE PREFERENCE TEST; ANHEDONIA; ANIMAL; DEPRESSIVE DISORDER; DRUG EFFECTS; METABOLISM; NERVE CELL; PARKINSONISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; RANDOMIZATION; SUGAR INTAKE; SWIMMING; WISTAR RAT;

ANHEDONIA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DIETARY SUCROSE; HIPPOCAMPUS; HYDROXYINDOLEACETIC ACID; MALE; NEURONS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PIROXICAM; RANDOM ALLOCATION; RATS, WISTAR; SEROTONIN; SUBSTANTIA NIGRA; SWIMMING;

EID: 84930682082     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.05.030     Document Type: Article

References (57)

1. Aarsland D., Pahlhagen S., Ballard C.G., Ehrt U., Svenningsson P. Depression in Parkinson disease: epidemiology, mechanisms and management. Nat Rev Neurol 2012, 8:35-47.
2. Bortolanza M., Wietzikoski E.C., Boschen S.L., Dombrowski P.A., Latimer M., Maclaren D.A., Winn P., Da Cunha C. Functional disconnection of the substantia nigra pars compacta from the pedunculopontine nucleus impairs learning of a conditioned avoidance task. Neurobiol Learn Mem 2010, 94(2):229-239.
3. Braun D., Longman R.S., Albert M.L. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005, 106(7):2375-2381.
4. Byrne G.I., Lehmann L.K., Kirschbaum J.G., Borden E.C., Lee C.M., Brown R.R. Induction of tryptophan degradation in vitro and in vivo: a γ-interferon-stimulated activity. J Interferon Res 1986, 6(4):389-396.
5. Calabrese J.R., Skwerer R.G., Barna B., Gulledge A.D., Valenzuela R., Butkus A., Subichin S., Krupp N.E. Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res 1986, 17:41-47.
6. Casarotto P.C., Andreatini R. Repeated paroxetine treatment reverses anhedonia induced in rats by chronic mild stress or dexamethasone. Eur Neuropsychopharmacol 2007, 17(11):735-742.
7. Catena-Dell'Osso M., Bellantuono C., Consoli G., Baroni S., Rotella F., Marazziti D. Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development?. Curr Med Chem 2011, 18(2):245-255.
8. Cimino C.R., Siders C.A., Zesiewicz T.A. Depressive symptoms in Parkinson disease: degree of association and rate of agreement of clinician-based and self-report measures. J Geriatr Psychiatry Neurol 2011, 24(4):199-205.
9. Dadashzadeh S., Vali A.M., Rezagholi N. LC determination of piroxicam in human plasma. J Pharm Biomed Anal 2002, 28:1201-1204.
10. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
11. Dantzer R., O'Connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36(3):426-436.
12. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995, 121:66-72.
13. Dombrowski P.A., Carvalho M.C., Miyoshi E., Correia D., Bortolanza M., Dos Santos L.M., Wietzikoski E.C., Eckart M.T., Schwarting R.K., Brandão M.L., Da Cunha C. Microdialysis study of striatal dopamine in MPTP-hemilesioned rats challenged with apomorphine and amphetamine. Behav Brain Res 2010, 215(1):63-70.
14. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctôt K.L. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67(5):446-457.
15. Fernandez H.H. Nonmotor complications of Parkinson disease. Cleve Clin J Med 2012, 79(2):14-18.
16. Ferro M.M., Bellissimo M.I., Anselmo-Franci J.A., Angellucci M.E., Canteras N.S., Da Cunha C. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods 2005, 148:78-87.
17. Frisina P.G., Haroutunian V., Libow L.S. The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat Disord 2009, 15:144-148.
18. Fujita I, Okumura T, Sakakibara A, Kita Y (2012) Involvement of inflammation in severe post-operative pain demonstrated by pre-surgical and post-surgical treatment with piroxicam and ketorolac. J Pharm Pharmacol 64:747-755.
19. Hirsch E.C., Vyas S., Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord 2012, 18(Suppl 1):S210-S212.
20. Hirsch E.C., Jenner P., Przedborski S. Pathogenesis of Parkinson's disease. Mov Disord 2013, 28(1):24-30.
21. Kahl K.G., Bens S., Ziegler K., Rudolf S., Dibbelt L., Kordon A., Schweiger U. Cortisol, the cortisol-dehydroepiandrosterone ratio, and pro-inflammatory cytokines in patients with current major depressive disorder comorbid with borderline personality disorder. Biol Psychiatry 2006, 59(7):667-671.
22. Knott C., Stern G., Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 2000, 16:724-739.
23. Kostic V.S., Djuricic B.M., Covickovic-Sternic N., Bumbasirevic L., Nikolic M., Mrsulja B.B. Depression and Parkinson's disease: possible role of serotonergic mechanisms. J Neurol 1987, 234:94-96.
24. Kuan-Pin S. Inflammation in psychopathology of depression: clinical, biological, and therapeutic implications. BioMedicine 2012, 2(2):68-74.
25. Kubera M., Obuchowicz E., Goehler L., Brzeszcz J., Maes M. In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):744-759.
26. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36(2):764-785.
27. Li M., Soczynsk J.K., Kennedy S.H. Inflammatory biomarkers in depression: an opportunity for novel therapeutic interventions. Curr Psychiatry Rep 2011, 13:316-320.
28. Lima M.M.S., Reksidler A.B., Zanata S.M., Machado H.B., Tufik S., Vital M.A. Different Parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res 2006, 1101:117-125.
29. Loftis J.M., Huckans M., Morasco B.J. Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol Dis 2010, 37:519-533.
30. Lu X., Ma L., Ruan L., Kong Y., Mou H., Zhang Z., Wang Z., Wang J.M., Le Y. Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. J Neuroinflamm 2010, 7:46.
31. Maes M., Leonard B., Fernandez A., Kubera M., Nowak G., Veerhuis R., Gardner A., Ruckoanich P., Geffard M., Altamura C., Galecki P., Berk M. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:659-663.
32. Malkesman O., Weller A. Two different putative genetic animal models of childhood depression: a review. Prog Neurobiol 2009, 88(3):153-169.
33. Mayeux R., Stern Y., Williams J.B., Cote L., Frantz A., Dyrenfurth I. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry 1986, 143:756-759.
34. Mayeux R., Stern Y., Sano M., Williams J.B., Cote L.J. The relationship of serotonin to depression in Parkinson's disease. Mov Disord 1988, 3:237-244.
35. Mayeux R (1990) Depression in the patient with Parkinson's disease. J Clin Psychiatry 51(Suppl):20-23 [discussion 24-25].
36. Menza M., Dobkin R.D., Marin H., Mark M.H., Gara M., Bienfait K., Dicke A., Kusnekov A. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010, 51:474-479.
37. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741.
38. Murase A., Okumura T., Sakakibara A., Tonai-Kachi H., Nakao K., Takada J. Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation. Eur J Pharmacol 2008, 580:116-121.
39. Nagatsu T., Mogi M., Ichinose H., Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 2000, 60:277-290.
40. O'Connor J.C., Andre C., Wang Y., Lawson M.A., Szegedi S.S., Lestage J., Castanon N., Kelley K.W., Dantzer R. Interferon- and tumor necrosis factor- mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 2009, 29(13):4200-4209.
41. Palhagen S., Qi H., Mårtensson B., Wålinder J., Granérus A.K., Svenningsson P. Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. J Neurol 2010, 257:524-532.
42. Papp M., Willner P., Muscat R. An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology (Berl) 1991, 104(2):255-259.
43. Paulus W.J., Ellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991, 50:743-755.
44. Paxinos G., Watson C. The rat brain in stereotaxic coordinates: the new coronal set 2005, Academic Press, San Diego. 5th ed.
45. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47(4):379-391.
46. Reneric J.P., Bouvard M., Stinus L. In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs. Behav Brain Res 2002, 136(2):521-532.
47. Santiago R.M., Barbieiro J., Lima M.M.S., Dombrowski P.A., Andreatini R., Vital M.A.B.F. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1104-1114.
48. Schrag A. Psychiatric aspects of Parkinson's disease: an update. J Neurol 2004, 251:795-804.
49. Shishodia S., Koul D., Aggarwal B.B. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-β activation through inhibition of activation of Iβ kinase and Akt in human nonsmall cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 2004, 173:2011-2022.
50. Song C., Wang H. Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:760-768.
51. Sostres C., Gargallo C.J., Arroyo M.T., Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010, 24(2):121-132.
52. Tadaiesky M.T., Dombrowski P.A., Figueiredo C.P., Cargnin-Ferreira E., Da Cunha C., Takahashi R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156:830-840.
53. Tan S.K.H., Hartung H., Sharp T., Temel Y. Serotonin-dependent depression in Parkinson's disease: a role for the subthalamic nucleus?. Neuropharmacology 2011, 61:387-399.
54. Teismann P., Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001, 39(2):167-174.
55. Thomas A.J., Davis S., Morris C., Jackson E., Harrison R., O'Brien J.T. Increase in interleukin-1 in late-life depression. Am J Psychiatry 2005, 162:175-177.
56. Vuckovic M.G., Wood R.I., Holschneider D.P., Abernathy A., Togasaki D.M., Smith A., Petzinger G.M., Jakowec M.W. Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis 2008, 32:319-327.
57. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 1997, 134:319-329.